Gilead Sciences Inc

Most Recent

  • uploads///SRPT
    Company & Industry Overviews

    A Look at Sarepta Therapeutics’ Stock Performance

    After its stellar rise from $54.02 on January 8 to a high of $161.51 on September 28, Sarepta stock has seen selling pressure amid the market volatility in October.

    By Kenneth Smith
  • uploads///revenue EE
    Earnings Report

    How Vertex’s Revenue and Earnings Surprised in 2Q16

    Vertex Pharmaceuticals (VRTX) reported its 2Q16 earnings on July 27, 2016. VRTX surpassed Wall Street analysts’ projections and reported revenue of $431.6 million.

    By Jillian Dabney
  • uploads///HIV
    Company & Industry Overviews

    Could Gilead Sciences’ Biktarvy Witness Solid Growth in 2018?

    In February 2018, the US FDA approved Gilead Sciences’ Biktarvy for the treatment of individuals with HIV-1 infection.

    By Daniel Collins
  • uploads///Graph
    Earnings Report

    How Gilead Sciences’ Gross Margin Outshines Its Peers

    Despite a year-over-year (or YoY) drop in revenues in 2Q16, Gilead Sciences (GILD) managed to earn gross margins of about 92%.

    By Margaret Patrick
  • uploads///Chart
    Earnings Report

    What Analysts Project for Eli Lilly in 3Q17

    For 3Q17, analysts estimate that Eli Lilly will post EPS of $1.03 on revenues of $5.5 billion.

    By Mike Benson
  • uploads///Relative valuation
    Earnings Report

    Regeneron Continues to Trade at Premium

    Regeneron is consistently trading at a premium compared to its peers. As of January 22, it was trading at a valuation multiple of 26.67x its earnings.

    By Jillian Dabney
  • uploads///Graph
    Earnings Report

    Amgen Continues to Control Operating Expenses in 3Q15

    In 3Q15, Amgen recorded total operating expenses of ~$3.4 billion. This fall in expenses enabled the company to report a net profit margin of ~36.4%.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Alexion Pharmaceuticals Adds Metabolic Drug Kanuma to Portfolio

    Kanuma was acquired by Alexion Pharmaceuticals on completion of the acquisition of Synageva Pharmaceuticals in June 2015.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Must-Read: Amgen’s 3Q15 Earnings and Conference Call

    In its 3Q15 earnings report released on October 28, Amgen reported YoY revenue growth of ~14.0%, from $5.0 billion in 3Q14 to $5.7 billion in 3Q15.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Analysts Expect Biogen’s Net Profit Margins to Rise in 3Q15

    Biogen’s (BIIB) 3Q15 earnings results will be announced on October 21, 2015. Analysts expect that the company will report lower net profit margins as compared to 2Q15.

    By Margaret Patrick
  • uploads///Orkambi
    Earnings Report

    How Vertex Pharmaceuticals’ Drugs Performed in 1Q18

    In 1Q18, Vertex Pharmaceuticals’ (VRTX) Orkambi revenue rose ~20% YoY (year-over-year) to $354 million from $295 million.

    By Daniel Collins
  • uploads///Graph
    Earnings Report

    AbbVie’s Viekira Pak Saw Weaker-than-Expected Performance

    Viekira Pak managed to earn revenues worth about $414 million in 1Q16. The drug’s sales in the US market, however, fell YoY (year-over-year) by about 9.3% and reached $125 million in 1Q16.

    By Margaret Patrick
  • Healthcare

    Third Point Partners ups stake in Amgen

    The fund noted in its letter that “Amgen has all the hallmarks of a hidden value situation, which is one of the fund’s favorite investment themes.”

    By Samantha Nielson
  • uploads///pill _
    Company & Industry Overviews

    Why Incyte Stock Fell ~9% on April 24

    On April 24, Incyte (INCY) stock fell ~9% on news regarding its drug Baricitinib, which is under FDA review.

    By Sarah Collins
  • uploads///dna _
    Earnings Report

    Sangamo Therapeutics Rose despite Q2 Sales Miss, Higher Losses

    Sangamo Therapeutics (SGMO) stock rose ~16% in afternoon trading. SGMO released its Q2 earnings results on August 8 after the market closed.

    By Sarah Collins
  • uploads///strensiq
    Earnings Report

    Inside Alexion’s Metabolic Drugs Kanuma and Strensiq

    In 1Q16, Strensiq added $33.2 million to Alexion Pharmaceuticals’ top line. Now the drug is in its initial launch phase in the US, Germany, and Japan.

    By Jillian Dabney
  • uploads///Graph
    Company & Industry Overviews

    Gilead Sciences’ Product Line Extension

    As part of its significant product line extension, Gilead Sciences (GILD) is entering therapeutic areas such as oncology, pulmonology, and cardiology.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    AbbVie Hopes to Commercialize Next-Generation HCV Regimen by 2017

    AbbVie (ABBV) plans to complete its Phase 3 registrational program for investigational next-generation Hepatitis C virus (or HCV) therapy by 2016.

    By Margaret Patrick
  • uploads///Chart  GILD
    Company & Industry Overviews

    Gilead Sciences Stock Performance in 1Q18

    Wall Street analysts estimate that Gilead Sciences (GILD) stock has the potential to return 21.1% over the next 12 months.

    By Mike Benson
  • uploads///Graph
    Earnings Report

    Biogen Trades at High Valuation Multiples Due to Strong Research Pipeline

    After the release of its 3Q15 earnings results on October 21, Biogen was trading at PE multiples in the range of 13.8x–15.3x.

    By Margaret Patrick
  • uploads///becdaabdacaceddd
    Earnings Report

    Johnson & Johnson Stock Remained Neutral to 2Q15 Earnings

    Due to the decelerating revenue growth over all segments, Johnson & Johnson (JNJ) reported a decrease in its top line by ~8.8% in its 2Q15 earnings release on July 14, 2015.

    By Mike Benson
  • uploads///genvoya
    Company & Industry Overviews

    How Could TAF-Based Regimen Drive Gilead Sciences’s Growth?

    Gilead Sciences’s (GILD) TAF-based (tenofovir alafenamide) regimen comprises three products: Genvoya, Descovy, and Odefsey.

    By Jillian Dabney
  • uploads///revue ee
    Earnings Report

    BioMarin’s Disappointing 3Q16 Earnings

    BioMarin Pharmaceutical (BMRN) reported its 3Q16 earnings on October 27, 2016. Revenues were $279.9 million, which was lower than Wall Street analysts’ projections.

    By Jillian Dabney
  • uploads///Graph
    Company & Industry Overviews

    AbbVie Strengthens Its Position in the Virology Segment

    In addition to Humira, AbbVie also offers several virology drugs targeting diseases such as hepatitis C, HIV, and respiratory syncytial virus.

    By Margaret Patrick
  • uploads///Chart  Rev EPS
    Company & Industry Overviews

    What’s Gilead Sciences’ Valuation?

    Gilead’s stock price has risen ~8.9% in the last 12 months. Wall Street analysts estimate that the stock price will fall ~4.5% over the next 12 months.

    By Mike Benson
  • uploads///Kanuma
    Earnings Report

    How Kanuma’s Addition to Alexion’s Portfolio Impacts Its Earnings

    Alexion added Kanuma to its portfolio in 2015 after its Synageva acquisition. But ALXN didn’t have much time to build diagnostics as it did with Strensiq.

    By Jillian Dabney
  • uploads///Graph
    Earnings Report

    Medicaid Restrictions Are Affecting Gilead’s Hepatitis C Drug Sales

    Since the launch of Sovaldi in late 2013, Gilead Sciences has managed to treat about 1,000,000 hepatitis C (or HCV) patients globally.

    By Margaret Patrick
  • uploads///Yescarta
    Company & Industry Overviews

    What Else Could Drive Gilead’s Long-Term Growth?

    In December 2017, Kite, a Gilead Sciences (GILD) company, presented long-term follow-up data from its pivotal ZUMA-1 trial of Yescarta.

    By Daniel Collins
  • uploads///hospital _
    Earnings Report

    Allergan’s 1Q18 Earnings: Analysts’ Estimates

    Allergan (AGN) plans to release its 1Q18 earnings on April 30. Wall Street expect AGN’s earnings per share to reach $3.36.

    By Mike Benson
  • uploads///Graph
    Miscellaneous

    FDA Granted Breakthrough Therapy Status to Merck’s HCV Therapy

    The U.S. Food and Drug Administration (or FDA) granted breakthrough therapy designation to Merck’s (MRK) grazoprevir/elbasvir (100mg/50mg) combination therapy.

    By Margaret Patrick
  • uploads///biology _
    Company & Industry Overviews

    Why Sangamo Therapeutics Stock Is Down More than 22% Today

    Today, Sangamo Therapeutics (SGMO) stock is down over 22% in afternoon trading. Yesterday, SGMO stock closed at $19.05.

    By Sarah Collins
  • uploads///chart_ __ _cresemba
    Company & Industry Overviews

    Pfizer Has Received Commercial Rights for Cresemba in Europe

    On June 14, 2017, Pfizer (PFE) announced an agreement with Basilea Pharmaceutica for exclusive commercial rights for Cresemba in Europe.

    By Mike Benson
  • uploads///Article
    Company & Industry Overviews

    Understanding Johnson & Johnson’s Ownership Structure

    As of January 2015, Johnson & Johnson’s ownership structure is dominated by passive investments. They account for more than 80% of the total ownership structure.

    By Mike Benson
  • fda approves gilead covid  drug remdesevir stock reacts
    News

    FDA Approves Gilead's COVID-19 Drug Remdesivir, Stock Reacts

    By Rachel Curry
  • uploads///covid  _
    Healthcare

    Gilead Sciences’ COVID-19 Drug Shows Promise

    Today at 7:55 AM ET, Gilead Sciences stock rose by 3.9% to $75.99 in the pre-market session. The company’s remdesivir drug might treat COVID-19.

    By Ambrish Shah
  • uploads///Apple stock
    Technology & Communications

    Norway’s Top Bank Scoops Up More Apple Stock

    Apple stock has emerged as investors’ darling in the technology sector this year, with investors piling into AAPL in recent months.

    By Ruchi Gupta
  • uploads///Graph
    Company & Industry Overviews

    Gilead Sciences’ Valuation Continues to Lag behind Peers

    Post 2014, Gilead Sciences has traded at lower valuation multiples, as investors are uncertain of the company’s ability to continue its leadership in the global HIV market.

    By Margaret Patrick
  • uploads///Analysts recommendation
    Company & Industry Overviews

    Analysts Recommendations for AbbVie in August 2017

    Twenty-one analysts were tracking AbbVie in August 2017. Three analysts suggested a “strong buy,” while seven suggested a “buy.”

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    What Do Analysts Recommend for AbbVie?

    Analysts updated their recommendations for AbbVie (ABBV) after the release of its 1Q16 earnings on April 28, 2016.

    By Margaret Patrick
  • uploads///GUIDANCE
    Company & Industry Overviews

    How’s Gilead Sciences Expected to Perform in 2016?

    Gilead Sciences lowered its guidance for fiscal 2016 due to weak 2Q16 results reported on July 25. It expects its 2016 revenues to be $29.5 billion–$30.5 billion.

    By Sarah Collins
  • uploads///Graph
    Earnings Report

    What Biogen Is Doing that Put It in Good Favor with Analysts

    Based on recommendations from 25 broker companies, a Bloomberg survey reported that 62.5% of analysts gave Biogen (BIIB) “buy” recommendations.

    By Margaret Patrick
  • uploads///Graph Part  Oct
    Company & Industry Overviews

    Baxalta in the XBI Top Ten Large Caps

    Baxalta (BXLT) rose by 6.2% for the week ending October 16, 2015. The stock rose as it received the Health Canada Approval for OBIZUR.

    By Peter Neil
  • uploads///Graph
    Earnings Report

    Gilead Sciences in 4Q15: Analysts Project Modest Revenue Growth

    On February 02, 2016, Gilead Sciences will announce its 4Q15 earnings for the period ending December 31, 2015. Analysts expect modest revenue growth.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    What Drove Gilead Sciences’ Hepatitis C Portfolio in 3Q15?

    Gilead Sciences’ (GILD) hepatitis C (or HCV) portfolio is expected to continue driving the company’s revenues and net profit margins in 3Q15.

    By Margaret Patrick
  • uploads///Graph Part
    Company & Industry Overviews

    Incyte Was a Star Performer from August 10–17, 2015

    By market cap size, Incyte (INCY) is among the top ten holdings of the SPDR S&P Biotech ETF (XBI). Incyte has a weight of 1.22% in XBI’s portfolio.

    By Peter Neil
  • uploads///Graph
    Earnings Report

    Celgene’s Operating Expenses in 3Q15

    In 3Q15, Celgene’s gross profit margin improved due to a favorable product mix composed mainly of Revlimid, Pomalyst, and Otezla.

    By Margaret Patrick
  • uploads///pill _
    Earnings Report

    Abbvie Up over 6% on 1Q18 Earnings Beat, Raised Earnings Forecast

    AbbVie (ABBV) released its 1Q18 earnings results for the quarter that ended on March 31 today.

    By Sarah Collins
  • uploads///Graph
    Company & Industry Overviews

    Inside AbbVie’s Analyst Recommendations in 2016

    Based on 24 recommendations, Bloomberg reported that 59.1% of analysts gave AbbVie a “buy” recommendation, while 36.4% of analysts gave the stock a “hold.”

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Celgene Estimates Robust Revenue in 2017

    In 2017, Celgene (CELG) expects to earn revenues of $13.0 billion–$13.4 billion, which would be a YoY (year-over-year) growth of around 18.0%.

    By Margaret Patrick
  • uploads///microscope _
    Earnings Report

    BeiGene’s Q2 2018 Earnings: Reports Revenue Growth

    BeiGene (BGNE) released its Q2 2018 earnings on August 9. BGNE surpassed analysts’ estimates for revenues but missed its EPS estimates.

    By Mike Benson
  • uploads///gilead sciences stock falls
    Healthcare

    Gilead Stock Falls, Coronavirus Drug Fails in Trial

    Today at 6:07 AM ET, Gilead Sciences stock fell 1.4% to $76.70 in the pre-market session. According to reports, remdesivir failed its first clinical trial.

    By Ambrish Shah
  • uploads///johnson and johnson earnings
    Earnings Report

    Will Johnson & Johnson’s Q1 Earnings Improve?

    Johnson & Johnson (NYSE:JNJ) stock has declined by 3.2% since the beginning of 2020. However, the stock has fared better than the broader market.

    By Sirisha Bhogaraju
  • Healthcare

    The Baupost Group ups its stake in Idenix Pharmaceuticals

    Idenix Pharmaceuticals (IDIX) accounted for a 6.25% position in Baupost’s fourth quarter portfolio. The hedge fund increased its stock holdings in Idenix last month.

    By Samantha Nielson
  • uploads///PART
    Basic Materials

    Let’s Explore How Cost Leadership Provides Market Control

    The attribute of “cost advantage” is the second most frequent source of economic moat ratings according to Morningstar. Companies that are able to produce and offer products or services at lower costs than competitors are often able to achieve much higher profit margins. Within many industries, cost leaders have a distinct competitive advantage and often […]

    By VanEck
  • uploads///business _
    Company & Industry Overviews

    Why Durect Corporation Is Soaring Today

    On July 22, Durect Corporation (DRRX) entered into a collaboration with HIV leader Gilead Sciences (GILD).

    By Margaret Patrick
  • uploads///business _
    Company & Industry Overviews

    Gilead Sciences Expands Collaboration with Galapagos

    On July 14, Gilead Sciences announced that it will expand its collaboration with Galapagos (GLPG).

    By Margaret Patrick
  • uploads///achievement _
    Company & Industry Overviews

    What Are Gilead Sciences’ Key Growth Drivers in Fiscal 2019?

    TAF-based HIV therapy Biktarvy and cell therapy Yescarta emerged as the key growth drivers for Gilead Sciences (GILD) in the first quarter. Besides these drugs, the company also expects HIV PrEP (pre-exposure prophylaxis therapies) Truvada and Descovy to be its key growth drivers in the future quarters.

    By Margaret Patrick
  • uploads///revenue _
    Company & Industry Overviews

    How Are Gilead Sciences’ Revenues Trending in 2019?

    In its first-quarter earnings investor presentation, Gilead Sciences (GILD) has projected fiscal 2019 product sales of $21.30 billion to $21.80 billion. Wall Street analysts have forecasted the company’s fiscal 2019 revenues to be $22.05 billion, a YoY decline of 0.36%.

    By Margaret Patrick
  • uploads///social media _
    Company & Industry Overviews

    What Are Analysts Recommending for Johnson & Johnson and Gilead?

    Johnson & Johnson (JNJ) is up by 10.10%, and Gilead Sciences (GILD) is up by 10.92% on a YTD basis. Both the companies are struggling due to intense competitive pressures either from branded or generic competitors. The consensus recommendation for both Johnson & Johnson and Gilead Sciences is a “buy.”

    By Margaret Patrick
  • uploads///graph _
    Company & Industry Overviews

    What to Expect from Johnson & Johnson and Gilead Sciences’ EPS

    In its first-quarter earnings press release, Johnson & Johnson (JNJ) has increased its fiscal 2019 adjusted diluted operational EPS guidance from the previously projected $8.65 to $8.80, which implies YoY growth of 5.7%–7.6%, to $8.73–$8.83, which implies a YoY rise of 6.7%–7.9%. The company also increased the lower end and narrowed its fiscal 2019 adjusted diluted EPS guidance from $8.50–$8.65.

    By Margaret Patrick
  • uploads///hand _
    Company & Industry Overviews

    How JNJ and Gilead Are Working to Expand Their Portfolios

    According to Johnson & Johnson’s first-quarter earnings conference call, Erleada gained a four-percentage-point market share in the US on a YoY basis. The drug is now being prescribed equally by urologists and well as oncologists, the two key prescribers for prostate cancer drugs.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Biktarvy to Have Strong International Revenue Performance

    Gilead Sciences (GILD) had launched Biktarvy in 19 European markets by the end of the first quarter.

    By Margaret Patrick
  • uploads///SGEN
    Company & Industry Overviews

    What Seattle Genetics’ Bottom-Line Trend Indicates

    In December 2018, of the total 13 analysts covering Seattle Genetics, eight analysts have given Seattle Genetics stock a “buy” or higher rating.

    By Kenneth Smith
  • uploads///dna _
    Company & Industry Overviews

    How’s Seattle Genetics Positioned?

    Seattle Genetics generated total revenues of $169.42 million in the third quarter of 2018 as compared with $135.29 million in the comparable period of 2017.

    By Kenneth Smith
  • uploads///molecule _
    Company & Industry Overviews

    Taking Stock of Sangamo’s Financial Performance

    In this series, we explore Sangamo’s financials, analysts’ views on the stock, and the company’s valuation metrics.

    By Kenneth Smith
  • uploads///pill _
    Company & Industry Overviews

    United Therapeutics: Recent Developments and Analysts’ Ratings

    On November 15, United Therapeutics (UTHR) entered into a global license agreement with Arena Pharmaceuticals (ARNA).

    By Daniel Collins
  • uploads///GILD
    Company & Industry Overviews

    Gilead Sciences: Analysts’ Recommendations

    In November, six analysts recommended a “strong buy,” ten recommended a “buy,” and 12 recommended a “hold” for Gilead Sciences.

    By Kenneth Smith
  • uploads///Chart
    Earnings Report

    Analysts Expect Incyte to Report Revenue Growth in Third Quarter

    Analysts estimate Incyte (INCY) to report growth of 17.7% in its revenues to $449.2 million during the third quarter of 2018.

    By Mike Benson
  • uploads///Imbruvica
    Company & Industry Overviews

    A Performance Overview of JNJ’s Imbruvica, Velcade, and Zytiga

    Johnson & Johnson’s (JNJ) Imbruvica generated revenue of $705.0 million in the third quarter.

    By Daniel Collins
  • uploads///Chart
    Earnings Report

    Amgen: Expect Nearly Flat Revenues in Q3

    New products are expected to deliver double-digit growth, while legacy brands are expected to offset the growth during the quarter.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Allergan’s Q3 2018 Estimates: Revenue Decline Expected

    Analysts are estimating that Allergan’s (AGN) third-quarter revenues will decline 3.8% to $3.88 billion.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Biogen: Analysts’ Recommendations on October 19

    For Biogen, eight analysts recommended a “strong buy,” 12 recommended a “buy,” and nine recommended a “hold.”

    By Mike Benson
  • uploads///SRPT
    Company & Industry Overviews

    Analyzing Sarepta’s Product Pipeline

    Sarepta is expected to incur R&D expenses of $277.8 million in fiscal 2018, compared with $166.71 million in fiscal 2017.

    By Kenneth Smith
  • uploads///capsule pill health medicine
    Company & Industry Overviews

    Celgene’s Financial Position before Its Third-Quarter Earnings

    Celgene is expected to report its third-quarter earnings on October 25. Celgene is expected to generate revenues of $3.8 billion in the third quarter.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    Cara Therapeutics: Performance and Estimates for Q3

    Cara Therapeutics reported revenues of $2.87 million in the second quarter compared to no revenues in the second quarter of 2017.

    By Mike Benson
  • uploads///GILD
    Company & Industry Overviews

    Analyzing Gilead Sciences’ Research Pipeline Developments

    On October 3, Gilead Sciences (GILD) reported the results from a phase three study evaluating Biktarvy’s safety and efficacy.

    By Kenneth Smith
  • uploads///Chart
    Company & Industry Overviews

    Allergan’s Stock Performance and Estimates for Q3 2018

    Wall Street analysts expect Allergan to report EPS of $3.98 on revenues of $3.8 billion in the third quarter.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Eli Lilly’s Earnings Quality and Dividend Performance

    Eli Lilly’s dividend yield is 2.11%. Its dividend yield last year was 2.46%, and its five-year average is 2.77%.

    By Mike Benson
  • uploads///thermometer _
    Company & Industry Overviews

    How GlaxoSmithKline Stock Has Performed in September

    Analyst estimates suggest GlaxoSmithKline stock could rise ~6.3% over the next 12 months.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Allergan’s SpotLyte and Lumivive System

    SpotLyte is the first venture from Project Moonwalker and is designed to educate consumers on medical aesthetics.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Here Are the Key Products in Sage’s GABA Receptor Portfolio

    Sage Therapeutics’ (SAGE) portfolio includes products under development for the treatment of life-threatening central nervous system (or CNS) disorders.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Shire’s Quarterly Revenue Trend

    Biotechnology company Shire (SHPG) reported a 4.6% YoY (year-over-year) rise in revenue to ~$3.9 billion in the second quarter.

    By Mike Benson
  • uploads///Virology
    Company & Industry Overviews

    Delstrigo, Pifeltro, and Merck’s Antiviral Therapy Portfolio

    Gilead Sciences’ Atripla, Genvoya, and Stribild generated revenues of $663.0 million, $2.2 billion, and $361.0 million, respectively, in the first half of 2018.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    Estimates and Recommendations for Bluebird Bio on September 6

    Wall Street analysts estimate that Bluebird Bio (BLUE) will report a 14.6% growth in revenues to ~$40.6 million in 2018 compared to $35.4 million in 2017.

    By Mike Benson
  • uploads///Rituxan
    Company & Industry Overviews

    An Overview of Roche’s Hemato-Oncology Drugs MabThera and Gazvya

    Roche’s (RHHBY) MabThera/Rituxan reported revenues of 3.45 billion Swiss francs in the first half compared to 3.8 billion Swiss francs in the first half of 2017.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    Examining Amgen’s Revenue Trend in Q2 2018

    Amgen reported a 4% rise in its year-over-year revenue to ~$6.06 billion in the second quarter compared to $5.81 billion in the first quarter of 2017.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Considering Allergan’s Q2 2018 Revenue Trend

    As discussed earlier, Allergan (AGN) reported a 2.9% rise in its YoY (year-over-year) revenue to $4.1 billion in the second quarter.

    By Mike Benson
  • uploads///medicine _
    Company & Industry Overviews

    Analyst Recommendations for Biogen and Its Peers in August

    On July 25, Biogen (BIIB) and Eisai announced positive results from the Phase 2 study evaluating BAN2401 in early Alzheimer’s disease.

    By Margaret Patrick
  • uploads///Chart
    Earnings Report

    What Analysts Recommend for Ionis after Q2 2018

    Wall Street analysts estimate Ionis Pharmaceuticals (IONS) will report year-over-year growth of ~34.8% in revenues to $612.5 million in 2018 as compared to revenues of $507.7 million during 2017.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Analysts Have Mixed Opinions about Ionis

    Wall Street analysts estimate that Ionis’s (IONS) Q2 2018 revenues will rise ~30.0% to $135.5 million as compared to $104.2 million in Q2 2017.

    By Mike Benson
  • uploads///EDIT
    Earnings Report

    Why Editas Medicine Stock Fell in July

    Editas Medicine’s (EDIT) general and administrative expenses are expected to rise 39.57% year-over-year in the second quarter.

    By Kenneth Smith
  • uploads///syringe _
    Earnings Report

    Incyte’s Q2 2018 Earnings Beat Analysts’ Revenue Estimates

    Incyte (INCY) beat Wall Street analysts’ estimates for revenue but missed estimates for EPS. It reported EPS of $0.27 on revenues of $521.5 million in Q2 2018.

    By Mike Benson
  • uploads///dna _
    Earnings Report

    What to Expect from Shire’s Q2 2018 Earnings on July 31

    Shire (SHPG) is set to release its Q2 2018 earnings on July 31. Wall Street analysts expect EPS of $3.67 on revenues of $3.8 billion.

    By Mike Benson
  • uploads///dna _
    Company & Industry Overviews

    PTC Therapeutics to Acquire Agilis Biotherapeutics

    On July 19, PTC Therapeutics (PTCT) agreed to acquire Agilis Biotherapeutics. The acquisition is expected to close during Q3 2018.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    Sage Therapeutics’ GABA Receptor–Based Products

    On June 12, Sage Therapeutics announced its expedited development plan for SAGE-217.

    By Mike Benson
  • uploads///dna _
    Company & Industry Overviews

    Amgen Announced the Phase 3 Results for ABP 710

    On June 27, Amgen (AMGN) announced the top-line results for the NCT02937701 study—a Phase 3 study evaluating safety and efficacy of ABP 710.

    By Mike Benson
  • uploads///healthcre
    Healthcare

    How the Healthcare Sector’s Dividend Yield Stacks Up

    The healthcare industry has an average dividend yield of 1.9%.

    By Amanda Lawrence
  • uploads///dna _
    Company & Industry Overviews

    Viking Therapeutics Stock Rose 101% on May 31

    On May 31, Viking Therapeutics (VKTX) closed at $9.99—a rise of ~101% from the previous day’s closing price of $4.97.

    By Sarah Collins
  • uploads///MEI
    Company & Industry Overviews

    What Led to MEI Pharma Stock’s 55% Rise Last Week?

    MEI Pharma (MEIP) saw a 55% rise in its stock price between May 11 and May 18.

    By Daniel Collins
  • uploads///GILD
    Company & Industry Overviews

    A Look at Gilead Sciences’ Financial Performance

    Gilead Sciences’ (GILD) total revenues decreased from $6.5 billion in Q1 2017 to $5.1 billion in Q1 2018 due to lower product sales.

    By Kenneth Smith
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.